ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1571

Elevated Lactate, Procalcitonin Levels and SIRS (Systemic Inflammatory Response Syndrome) in a Subset of Patients with Gout

Christopher Podgorski1, Paula Skarda2 and Elie Gertner3, 1Department of Medicine, University of Minnesota Medical School, Saint Paul, MN, 2Department of Medicine, Regions Hospital, University of Minnesota Medical School, Saint Paul, MN, 3Section of Rheumatology, Regions Hospital and Division of Rheumatology, University of Minnesota Medical School, Minneapolis, MN

Meeting: ACR Convergence 2021

Keywords: Crystal-induced arthritis, gout, hyperuricemia, Inflammation

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II (1565–1583)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: The intense inflammatory cascade of acute gouty inflammation makes it difficult to differentiate clinically between acute gouty inflammation and sepsis, particularly since they can occur together. A SIRS-like presentation attributed to acute gouty inflammation has been described sporadically 1-6. In these cases, sepsis is usually considered first, and markers such as lactate and procalcitonin are used to confirm the diagnosis of sepsis. Gout is not even considered as a possibility. However, delayed diagnosis and treatment of gout when it is the cause of the presentation leads to unnecessary antibiotic use and prolonged hospitalization.

We describe a cohort of patients who presented with SIRS, elevated lactate (some markedly high) and/or elevated procalcitonin and even concerning NEWS2 (National Early Warning Scores) scores due to acute gout alone. While sepsis must always be ruled out, we describe those characteristics that may suggest that gout, rather than sepsis, is the presenting cause.

Methods: Retrospective chart review of patients with a gout related hospital encounter between 2014 and 2017 at Regions Hospital. Of 1,041 such episodes, 14 encounters had ≥2 SIRS criteria, elevated lactate/procalcitonin and were admitted for presumed sepsis. Demographics, clinical presentation, laboratory and imaging data are summarized in Table 1.

Results: There were 14 patient encounters including 11 patients with one episode and one with three separate similar presentations. All were male, mean age 58.6 years, mean time since gout diagnosis 11.2 years, 8 patients (66.6%) had tophi, and 10 patients (83.3%) had history of ≥5 gout flares. Mean lactic acid was elevated in 12/14 ranging from 2-12.2 mmol/L (normal 0.5-2.0 mmol/L), and procalcitonin was 0.23-2.79 ng/mL (< 0.24 ng/ml). Use of antibiotics beyond the first 24 hours of admission was seen in 7 presentations (58.3%). No infection was identified. While many patients were concurrently treated with antibiotics for presumed bacterial sepsis, the patient cohort showed rapid clinical improvement within 24-48 hours of starting appropriate gout therapy. Hospital courses are summarized in Table 1.

Conclusion: A SIRS-like presentation with elevated lactate and procalcitonin levels occurs in a subset of gout patients. A high index of suspicion for a gout flare is indicated if patients have a) history of gout of >10 years duration b) tophi c) > 5 gouty flares. Early recognition of gout as the cause of the marked inflammatory response can limit unnecessary antibiotic use and prolonged hospitalization. Hospitalists, emergency physicians and rheumatologists should be aware of this subset of gouty patients.

References
1. Nicholls DW, et al. N Z Med J. 1999 Nov 12;112(1099):434-5.
2. Shah D, et al. Am J Med. 2015 Jul;128(7):e11-2.
3. Gago R, et al. BMJ Case Rep. 2018 Jan 24;1-3.
4. Cheung M, et al. JICS. 2012 Jan;13(1):57-8.
5. Peng L, et al. Unresolving Sepsis: When in Doubt, Consider Gout. Presented at OHSU.
6. Schafer VS, et al. JSM Arthritis. 2017 Aug;2(2):1024.


Disclosures: C. Podgorski, None; P. Skarda, None; E. Gertner, None.

To cite this abstract in AMA style:

Podgorski C, Skarda P, Gertner E. Elevated Lactate, Procalcitonin Levels and SIRS (Systemic Inflammatory Response Syndrome) in a Subset of Patients with Gout [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/elevated-lactate-procalcitonin-levels-and-sirs-systemic-inflammatory-response-syndrome-in-a-subset-of-patients-with-gout/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/elevated-lactate-procalcitonin-levels-and-sirs-systemic-inflammatory-response-syndrome-in-a-subset-of-patients-with-gout/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology